Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $45,472,119 | $45,909,270 | $42,538,512 | $43,662,894 |
| - Cash | $2,685,600 | $3,272,800 | $3,140,600 | $3,045,200 |
| + Debt | $700,300 | $702,600 | $699,400 | $700,000 |
| Enterprise Value | $43,486,819 | $43,339,070 | $40,097,312 | $41,317,694 |
| Revenue | $1,553,100 | $1,532,200 | $1,412,700 | $1,385,800 |
| % Growth | 1.4% | 8.5% | 1.9% | – |
| Gross Profit | $1,209,600 | $1,189,600 | $1,111,100 | $1,093,600 |
| % Margin | 77.9% | 77.6% | 78.7% | 78.9% |
| EBITDA | $387,600 | $400,200 | $470,500 | $483,700 |
| % Margin | 25% | 26.1% | 33.3% | 34.9% |
| Net Income | $291,100 | $329,800 | $358,000 | $385,600 |
| % Margin | 18.7% | 21.5% | 25.3% | 27.8% |
| EPS Diluted | 0.5 | 0.56 | 0.61 | 0.65 |
| % Growth | -10.7% | -8.2% | -6.2% | – |
| Operating Cash Flow | $573,700 | $290,200 | $280,400 | -$127,500 |
| Capital Expenditures | -$57,500 | -$49,300 | -$56,000 | -$49,800 |
| Free Cash Flow | $516,200 | $240,900 | $224,400 | -$177,300 |